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Summary 
gp39,  the ligand for CD40  expressed on activated CD4 + T  helper cells,  is required for the 
generation of antibody responses to T-dependent (TD) antigens. Treatment of mice with anti- 
gp39 in vivo inhibits both primary and secondary antibody formation to TD, but not T-independent 
antigens. However, the role of this receptor-ligand pair in the development of germinal centers 
and the generation of B cell memory is as yet undefined. Using an antibody to gp39, this study 
examines the in vivo requirement for gp39-CD40 interactions in the induction of germinal center 
formation, as well as in the generation of B cell memory. Animals were immunized, treated 
in vivo with anti-gp39, and evaluated using immunohistochemical staining for the presence of 
splenic germinal centers 9-11 d after immunization. The results demonstrate that the formation 
of germinal centers was completely inhibited as a result of treatment with anti-gp39. Moreover, 
adoptive transfer experiments demonstrate that the generation of antigen-specific memory B cells 
is also inhibited as a consequence of blocking gp39-CD40 interactions. Taken together, the data 
demonstrate that gp39-CD40  interactions are critical not only for the generation of antibody 
responses, but  also in the development of B cell memory. 
E 
vidence from a number of studies demonstrate that the 
interaction between gp39, a molecule expressed on acti- 
vated Th cells, and CD40, its mitogenic receptor on B lym- 
phocytes, provides the essential signal for the induction of 
B cell activation and Ig production. In vitro studies have shown 
that a mAb specific for gp39 (1) and soluble CD40-Ig (2, 
3) block the capacity of gp39-bearing Th cells to activate B 
cells. Moreover, it has recently been demonstrated that in vivo 
administration of anti-gp39 inhibited both primary and sec- 
ondary humoral immune responses to a variety of thymus- 
dependent  (TD) 1 antigens  (4,  5).  The  anatomical  site  at 
which gp39 expression is most evident is in the periphery 
of the periarteriolar lymphoid sheath (PALS), where it has 
been shown to be expressed on CD4 + T  cells as a conse- 
quence of antigen administration.  Furthermore, the gp39- 
expressing T ceils have been shown to be juxtaposed to the 
B cells producing Ab specific to the immunizing antigen (5). 
Further evidence that gp39-CD40 interactions are essential 
for the generation of humoral responses comes from genetic 
studies of patients with hyper-IgM syndrome (HIM), an im- 
1 Abbreviations used in this~per: Hlg, hamster  Ig; HIM, hyper-IgM;  PNA, 
peanut agglutinin; TD, thymus dependent. 
munodeficiency characterized by the inability to respond to 
TD antigens (for a review see reference 6). A number of studies 
have demonstrated that the failure of these patients to mount 
humoral responses to TD antigens can be attributed to mu- 
tations in the gene encoding gp39, confirming the require- 
ment for this molecule in Ab-mediated immunity to TD an- 
tigens (7-11). 
Although it has been established that gp39-CD40 inter- 
actions are essential for the development of both primary and 
secondary humoral responses,  the role of this receptor-ligand 
pair in the development of germinal centers and the genera- 
tion of B cell memory is as yet unknown. Germinal centers 
are histologically distinct regions of the spleen consisting of 
clusters of actively proliferating B cells that develop transiently 
within the primary follicles  of secondary lymphoid organs 
as a consequence of antigenic stimulation. It has been demon- 
strated that B cells within a germinal center undergo antigen- 
driven oligoclonal proliferation (12, 13). Germinal centers are 
also  believed to be the anatomical sites  in  which isotype 
switching and affinity maturation occur (14-18).  In addition, 
antigen-specific memory B cell clones (19-21) and plasma cell 
precursors are thought to be generated within the germinal 
center (22). 
It has been established that T cells are critically important 
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required to drive proliferation, differentiation, and memory 
B cell formation within the germinal center microenviron- 
ment have yet to be elucidated. However, some evidence exists 
which suggests that gp39-CD40 interactions may play a role. 
Patients with HIM syndrome have no detectable germinal 
centers and lack B cell memory (6), suggesting that gp39 
may be required for germinal center formation and the gener- 
ation of memory B cells within them. Indirect in vitro evi- 
dence that gp39-CD40 interactions may play a role in the 
germinal center reaction is provided by studies demonstrating 
that Ab-mediated ligation of CD40 prevents germinal center 
cells from undergoing apoptosis, a suggested mechanism for 
the establishment of a memory B  cell pool (27,  28).  Em- 
ploying a mAb specific for gp39, this study examines the in 
vivo requirement for gp39-CD40 interactions in the forma- 
tion  of germinal  centers  and  in  the  generation  of B  cell 
memory. Immunohistochemical analysis of splenic sections 
from immune animals revealed  that in vivo administration 
of anti-gp39 prevented the formation of germinal centers as 
detected by both peanut agglutinin (PNA) and membrane 
IgD (m~) staining. Moreover, adoptive transfer of splenic B 
cells  from anti-gp39-treated mice demonstrated a lack  of 
antigen-specific memory B cells in the treated animals.  Taken 
together, these data demonstrate that gp39-CD40 interac- 
tions are not only critical in the generation of humoral re- 
sponses, but also in germinal center formation and the gener- 
ation of B cell memory. 
Materials  and Methods 
Animals.  Female, 6-8-wk-old BALB/c and  CB17 (BALB/c 
Igh  b congenic) mice (The Jackson Laboratory, Bar Harbor, ME) 
were used for the in vivo experiments presented in this  study. 
Animals were maintained in the specific pathogen-free animal fa- 
cility at Dartmouth Medical School. 
Reagents and Abs.  SRBC were purchased from Colorado Serum 
Co. (Denver, CO). KLH (from Megathura crenulata) was purchased 
from Pacific  Marine Biolabs (Inglewood, CA). TNP-KLH and TNP- 
BSA were prepared as previously described (29). CFA for immuni- 
zations was obtained from Sigma Chemical Co. (St. Louis, MO). 
MR1, hamster anti-routine gp39 mAb (1) was purified by DEAE 
HPLC from ascites fluid. Hamster Ig (HIg), used as a control Ab, 
was purified similarly from hamster serum (Accurate Chemical and 
Scientific Corp., Westbury, NY). 10.4.22, a rat anti-murine IgD, 
was kindly supplied by Dr. Thomas Waldschmidt (University of 
Iowa, Iowa City, IA) (30). 412-49.7-20, a mAb mouse anti-mu- 
fine IgG1  b, was a kind gift of Dr. Fred Finkelman (Uniformed 
Services University of the Health Sciences, Bethesda, MD) (31). 
PNA-biotin,  avidin-horseradish peroxidase (HRP),  and  3,3  di- 
aminobenzidine  tetrahydrochloride (DAB) were purchased from 
Sigma Chemical Co. 
Anti-gp39 Treatment.  HPLC-purified anti-gp39 (MR1) or HIg 
(as an Ab control)  was administered (250 #g/injection, i.p.) on 
days 0, 2, and 4 after immunization  or as indicated for each ex- 
periment. 
Immunizations.for the Generation of Primary Ab Responses.  For 
the generation of  primary anti-sheep erythrocyte  responses and in- 
duction of germinal center formation,  mice were immunized in- 
traperitoneally with 100 #1 of a 10% solution of SRBC. Animals 
were killed on day 9 or 11 and immunohistochemistry  was per- 
formed to detect the presence of germinal centers. 
Immunohistochemistry.  Splenic  tissue was obtained on day 9 or 
11 after immunization,  snap-frozen in liquid nitrogen, and stored 
at  -80~  until use. 8-#m sections were cut, stored overnight in 
a humified atmosphere, and fixed  for 10 min the following day in 
fresh acetone containing  0.02%  H202.  Sections were then air- 
dried for 10 min and incubated with either PNA-biotin or anti- 
IgD-biotin in PBS/0.1% BSA for 1 h at room temperature. After 
washing three times with PBS, sections  were incubated with avidin- 
HRP for an additional hour at room temperature. Sections were 
washed  and  subsequently  stained with  DAB  in  0.05  M  Tris- 
HC1/H202,  pH 7.6,  for 10 rain.  After washing, sections were 
counterstained with hematoxylin and embedded with Glycergel 
(Dako Corp.,  Carpinteria,  CA). 
Adoptive Transfer of Memory B Cells.  CB17  (Igh  b) mice were 
immunized with 100 #g TNP-BSA (CFA) to induce formation of 
memory B cells. 4 wk later, B cells from these animals were adop- 
tively transferred into irradiated (600 rad) KLH-primed  (100 #g 
in CFA, i.p.) BALB/c recipient mice. Mice were challenged with 
10 #g soluble TNP-KLH at the time of transfer. On day 7, serum 
was obtained and serum anti-TNP IgG1  b Ab levels assessed using 
a TNP-specific ELISA. 
Antigen-specific Allotype-specific ELISAs.  A TNP-specific  ELISA 
was used to determine the IgG1  b anti-TNP titers. Briefly, antigen 
(1 mg/ml TNPr-OVA) was absorbed onto flexible polyvinyl mi- 
crotiter dishes, overnight at 4~  Plates were washed and blocked 
with PBS-1% FCS-sodium-azide. Diluted serum samples were in- 
cubated for 2 h at 37~  Samples were washed and the TNP-specific 
IgG1  b Ab titers determined with biotin-conjugated  anti-IgG1  b, 
followed by avidin-alkaline-phosphatase (Zymed Laboratories, Inc., 
South San Francisco, CA) as detection. ELISAs were developed  by 
reaction of alkaline-phosphatase with phosphatase substrate (Sigma 
Chemical Co.). Plates were analyzed on an ELISA reader (model 
MR700;  Dynatech Laboratories Inc., Chantilly, VA) at 410 rim. 
For antigen-specific ELISAs, the units represent arbitrary values 
based on the titration curve of a standard immune serum. All ex- 
perimental groups were titered from 1:50 to 1:100,000 and the titer 
ascertained based on multiple point analysis. 
Results 
In Vivo Anti-gp39  Treatment Prevents the Formation of Ger- 
minal Centers in Immune Animals.  It has been established that 
germinal  center formation is  a  T  cell-dependent  process 
(23-26). Moreover, in vitro studies have suggested that the 
CD40 molecule may also play a role in the germinal center 
reaction (27, 32). Therefore, experiments were designed to 
determine whether the ligand for CD40, gp39, was required 
for the antigen-induced formation of germinal centers. Using 
an Ab specific for gp39, we examined the effect of blocking 
gp39-CD40 interactions on germinal center formation. An- 
imals were immunized with SRBC, a TD antigen, and treated 
with anti-gp39 or control HIg on days 0, 2, and 4. On days 
9 and 11, immunohistochemical staining was performed on 
spleen sections from both nonimmune and immune, treated 
animals. Germinal center formation was assessed by expres- 
sion of PNA  and m& 
B cells undergo characteristic antigen-induced transitions 
within the follicle as a result of antigen exposure (for a re- 
view see reference 33). After immunization, antigen-specific 
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tion from a m~ + phenotype to m~-  (21, 34). Furthermore, 
germinal center B cells attain the ability to bind high levels 
of the lectin PNA, in contrast to follicular B cells which re- 
main PNA-  (14, 21,  35). Fig.  I  (left) depicts splenic sections 
from  SRBC-immune  mice  treated  with  control  HIg  and 
stained with PNA (.4) or anti-~ (C). Immune mice develop 
extensive germinal centers within the primary follicles. These 
germinal centers are composed of large clusters of actively 
proliferating B cells expressing high levels of PNA binding 
sites  (A).  Within  the  germinal  center,  a peripheral  region 
of m~ +  B  cells  surrounds  the actively proliferating PNA + 
B cells (C). Treatment with anti-gp39, at the time of immu- 
nization, results in the complete inhibition of germinal center 
formation  (right).  Splenic  sections  from  anti-gp39-treated 
animals  showed almost  complete absence of PNA-binding 
cells (B).  Although  some PNA-binding  was  visible in  the 
stromal elements of the splenic mantle zone area, this staining 
pattern was also observed in animals treated with control Ab. 
Analysis of the m~ + staining also confirmed the lack of ger- 
minal centers in anti-gp39-treated  animals.  As seen in Fig. 
1  D,  large  primary  follicles composed  of m~ + ,  resting  B 
cells are present in the spleens of animals treated with anti- 
gp39.  This  is  in  contrast  to  the  PNA +,  m6-  germinal 
centers within secondary follicles observed in HIg-treated im- 
mune  animals. 
A  quantitative analysis of primary follicles and secondary 
follicles containing germinal centers present in immune mice 
treated with either control HIg or anti-gp39 is summarized 
in Table 1. Splenic sections from animals treated as described 
in Fig.  1 were analyzed quantitatively for m/~-, PNA + ger- 
minal centers as well as m/~ + primary follicles. The data are 
expressed as the number of germinal centers or primary fol- 
licles visible in seven splenic sections.  Table 1 demonstrates 
Figure 1.  In vivo anti-gp39 treatment prevents the formation of germinal centers. Mice (three to four per group) were immunized with 100 #1 
of 10% SKBC i.p. on day 0. On days 0, 2, and 4 mice were treated with 250 #g of hamster Ig (A and C), or anti-gp39 (B and D). Spleens were 
removed on day 9 or 11 and immunohistochemistry was performed. Sections  were stained for PNA (A and B) to detect PNA-binding germinal center 
memory B cells, or IgD (C and D) to visualize IgD + follicular B cells. In control-treated animals (-4 and C), large clusters of brightly PNA-staining 
B cells comprising the germinal centers are visible. IgD + follicular  B cells are displaced into the peripheral zone around the actively  proliferating ger- 
minal center B cells. In anti-gp39-treated animals (B and D), very few PNA-staining B cells are visible and no full-size germinal centers are present. 
Primary follicles  containing almost entirely IgD + B cells are abundant with only rare follicles transforming to germinal centers. Primary follicles (]) 
and germinal centers (gc) are noted. (,4 and C)  x20,  (B)  x25, and (D)  xl0. 
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Treatment*  PNAt  IgD § g  IgD- 
(days  after  (germinal  (primary  (germinal 
immunization)  centers)  follicles)  centers) 
Control (day 9)11  63.5  _+  13.5~  37.0  _+  6.1  65.5  _+  9.9 
Control (day 11)  53.0  _+ 22.9  46.7  _+  7.6  50.3  -+  30.0 
Anti-gp39  (day 9)  3.0  _+ 3.5  96.7  _+  17.6  6.0  _+ 4.6 
Anti-gp39  (day 11)  5.7  _+  8.1  97.7  _+  6.8  18.3  _+ 9.5 
* Mice (three to four per group) were immunized with 100 #l of 10% SRBC on day 0 and treated with control (Hlg) or anti-gp39 (250 #g/injection) 
on days 0, 2, and 4. 
t PNA-binding was used for the detection of germinal center B cells. 
Anti-IgD  was used for the detection of primary follicles (mr5+). 
II Spleens were removed on day 9 or 11 and immunocytochemistry was performed on frozen sections. 
￿82  The data are representative of two experiments in which three to four animals were analyzed per group and are expressed as the mean number 
of germinal centers or follicles detected in seven frozen sections of 8-#m thickness. 
that  anti-gp39  treatment  drastically decreased the number 
of PNA +, m~5- germinal centers that form as a result of im- 
munization with sheep erythrocytes. Moreover, me5 staining 
indicates that the number of primary follicles present in anti- 
gp39-treated  animals  is  significantly greater than  that  ob- 
served in control-treated animals,  indicating an absence of 
follicular B  cells transforming to germinal center, memory 
B cells. Overall, splenic sections from immune animals treated 
with anti-gp39 were indistinguishable from those of nonim- 
mune animals (data not shown).  Taken together, immuno- 
histochemical analysis demonstrates that anti-gp39 treatment 
inhibits the formation of germinal centers within the spleens 
of immunized  animals. 
To establish  that  anti-gp39  treatment  does not interfere 
with the capacity of follicular dendritic cells (FDC) to trap 
immune complexes, a process thought  to be crucial for in- 
duction of B cell memory, mice were treated with anti-gp39 
on  days  0,  2,  and  4  before administration  of peroxidase- 
antiperoxidase  immune  complexes  (200  #1  i.v.)  on  day 5. 
Spleens were taken for immunohistochemistry on day 6, and 
trapped immune complexes were revealed by DAB-staining. 
No differences in the pattern of immune complex trapping 
in the spleen were found between animals treated with anti- 
gp39 or control HIg (results not shown). These results dem- 
onstrate that the immune complex trapping function of FDC 
is not impaired by anti-gp39. 
In Vivo Anti-gp39 Treatment Inhibits the Generation of  B Cell 
Memory in Immune Mice.  Germinal centers are believed to 
be the site of generation of memory B cells within the splenic 
B cell compartment (19-21). Although the previous experi- 
ment showed that anti-gp39  treatment inhibits  the forma- 
tion  of PNA +  germinal  centers,  it  is  important  to  assess 
whether the generation of functional B cell memory is also 
inhibited. The definition of functional B cell memory is the 
ability of B cells to elicit a secondary Ab response upon chal- 
lenge with  soluble antigen after adoptive transfer (36-41). 
To assess the effect of anti-gp39 treatment on the generation 
of functional B  cell memory,  CB17  (Igh  b)  mice were im- 
munized with TNP-BSA and treated with HIg or anti-gp39. 
After 4 wk,  splenic B  cells from these animals were adop- 
tively transferred into  KLH-primed BALB/c  (Igh a) recipi- 
ents. Animals were subsequently challenged with TNP-KLH 
and the level of donor-specific IgG1  b anti-TNP Abs was de- 
termined. The results, shown in Fig. 2, demonstrate that B 
cells from untreated or HIg-treated animals immunized with 
TNP-BSA produce high levels of donor-specific IgG1 b anti- 
none 
naive 
control 
HIg 
anti-gp39 
B cell 
source 
Figure 2. 
0  1000  2000  3000 
IgG1 banti-TNP  (units) 
In vivo anti-gp39 treatment inhibits the generation of B cell 
memory. CB17 (Ighb congenic strain of BALB/c) mice were immunized 
with TNP-BSA (100 #g in CFA) and administered anti-gp39 or HIg (on 
days 0, 2, and 4; 250 #g/d). After 4 wk, B cells were adoptively trans- 
ferred into irradiated (600 rad) KLH-primed BALB/c recipients. Subse- 
quently, animals were  challenged  with 10 #g soluble  TNP-KLH, i.p. Serum 
IgG1  b anti-TNP titers were ascertained on day 7 after transfer. Units 
represents arbitrary values based on the titration curve of a standard im- 
mune serum. All experimental  groups were titered from 1:100 to 1:100,000 
and the titer ascertained based on multiple point analysis. The data are 
representative of two such experiments. 
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However,  the level of donor-specific IgG18 anti-TNP Abs 
produced by animals which received B cells from animals 
treated with anti-gp39 was inhibited by >80%. This experi- 
ment confirms that the absence of germinal centers can be 
correlated to the lack of  functional B cell memory, and demon- 
strates that blocking gp39-CD40 interactions directly inhibits 
the generation of  functional memory  B cells. These data, along 
with the immunohistochemical data, collectively support the 
tenet that gp39-CD40 interactions are critical in the forma- 
tion of germinal centers as well as in the generation of B 
cell memory. 
Discussion 
The triggering of CD40 through its interaction with gp39 
is essential for the generation of TD humoral immune re- 
sponses in vivo (4, 5). This study examines the in vivo re- 
quirement for gp39-CD40 interactions in the formation of 
germinal centers and in the generation of B cell memory. 
In vivo administration of anti-gp39 prevented the formation 
of germinal centers as detected by immunohistochemical anal- 
ysis of splenic sections from immune animals. Both the de- 
velopment of germinal center PNA-binding B cells and the 
transition of primary follicular m/~ + B cells to m/~- germi- 
nal center B cells were inhibited  as a result  of anti-gp39 
treatment. Adoptive transfer of primed B cells from anti- 
gp39-treated mice demonstrated that blocking this interac- 
tion also resulted in a profound inhibition of Ab production 
by antigen-specific memory B cells. 
Germinal centers arise in the follicles of secondary lym- 
phoid tissue as a result of antigenic challenge. It is known 
that upon antigenic challenge, germinal centers become sites 
of extensive oligoclonal B cell proliferation  (12, 13). Once 
activated, resting follicular m/~  + B cells mature and prolifer- 
ate to form large dusters of m~-, PNA-binding cells (14, 
21, 34, 35). Somatic mutation, isotype switching, and antigen- 
specific B cell memory are all believed to occur within the 
specialized microenvironment of the germinal center (14-21). 
However, the precise sequence of signaling events required 
to drive the germinal center reaction are as yet unknown. 
The requirement for T  cells in the formation of germinal 
centers has been demonstrated by examination of nude mice 
which fail to form germinal centers after antigenic challenge, 
but upon reconstitution with T cells, develop normal ger- 
minal centers (23). Although the requirement for T cells in 
the germinal center reaction seems clear, whether these T 
cells  provide  contact-dependent or  lymphokine-mediated 
signals is as yet unresolved. 
Several crucial pieces of evidence tend to support a role 
for gp39-CD40 interactions in the germinal center reaction. 
First, it is clear that signaling through CD40 either via anti- 
CD40 mAbs or its ligand results in extensive B cell prolifera- 
tion, a primary event in the germinal center reaction. Second, 
several investigators  have demonstrated in vitro that anti-CD40 
Abs prevent B cells from undergoing programmed cell death 
within the germinal center (27, 32), demonstrating a role 
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for CD40 in the survival of germinal center B cells. It has 
been suggested that this is a possible mechanism for rescuing 
germinal  center B cells for the purpose of establishing  a 
memory B cell pool (27). Finally, additional  evidence that 
signaling through CD40 and its ligand, gp39, is critical for 
germinal center formation is  provided  by HIM  patients. 
HIM patients lack the expression of gp39 or express mutant 
gp39 molecules which are incapable of CD40 binding (7-11). 
It is  important to note that these  patients  lack germinal 
centers and functional B cell memory, suggesting that signals 
provided by gp39-CD40 interactions  may be essential for 
these processes (6). 
The hypothesis that gp39-CD40 interactions  are critical 
for the development  of B cell memory hinges  on the fact 
that anti-gp39 does not delete or functionally alter Th cells. 
If either of these occur, then it is possible that the gp39-CD40 
pair may only be indirectly involved in the generation of B 
cell memory. A number of lines of evidence strongly suggest 
that anti-gp39  does not alter Th cell number or function. 
First, antigen-specific  Th cells from anti-gp39-treated animals 
can readily transfer helper function to recipients, indicating 
that Th cells are neither functionally silenced nor physically 
deleted as a consequence of in vivo anti-gp39 administration 
(4). Second, in situ, the frequency  of IL-2-, IL-4-, and IFN- 
y-producing T cells in immune anti-gp39-treated or untreated 
mice is identical, indicating that anti-gp39 does not diminish 
the frequency of lymphokine-producing T cells (5). Third, 
anti-gp39 does not diminish the humoral immune response 
to T-independent type II antigens, a response that is depen- 
dent upon endogenous lymphokine production for maximal 
responsiveness (4, 5). Fourth, anti-gp39 in vitro does not alter 
the proliferation  of TCR transgenic T ceils in response to 
the corresponding antigen, suggesting that anti-gp39 binding 
to gp39 does not exert a negative signal (Noelle, R. J., un- 
published observation).  Therefore, the mechanism of gp39 
inhibition of memory  is likely through the blockade of ligand 
binding to CD40. One additional assumption in this hypoth- 
esis is that gp39 expressed on activated T cells is responsible 
for the induction of B cell memory via binding to CD40 
expressed on antigen-specific B cells. With the expression of 
gp39 on non-T cells (mast cells and basophils [42]) and CD40 
on non-B cells (macrophages [43] and thymic epithelium [44]) 
other hypotheses are possible, but less likely. 
The evidence provided in this study supports the hypoth- 
esis that gp39-CD40 interactions are critical for the genera- 
tion of germinal centers and B cell memory. In vivo adminis- 
tration  of anti-gp39  during  antigen  exposure  results  in 
profound inhibition of the formation of germinal centers 
within the spleens of immunized animals, as well as in the 
generation of functional memory B cells. The fact that in 
vivo anti-gp39  treatment probably inhibits  Ab production 
in both primary and secondary responses through the blockade 
of gp39 binding to CD40, along with evidence indicating 
that antigen-specific and lymphokine-producing  Th cells are 
not deleted after in vivo administration of anti-gp39,  sup- 
port the tenet that the processes of germinal center forma- 
tion and memory B cell development are also prevented by 
blocking gp39-CD40-mediated signals. The inhibition of gp39-CD40-dependent humoral immune 
responses has also been examined through the use of the soluble 
fusion protein CD40-Ig. Our laboratory has previously de- 
termined that in vivo administration of human CD40-Ig does 
not block the generation of primary Ab responses  (Noelle, 
R. J., unpublished observation). This observation could be 
due to the low affinity of human CD40 Ig for routine gp39. 
However, a recent study (45) examining the effects of CD40-Ig 
in vivo demonstrated that soluble murine CD40-Ig did not 
block the generation of humoral immune responses  or the 
formation of germinal centers.  Lane et al. (45) showed that 
transgenic mice expressing serum levels of 10-30 #g/ml of 
murine CD40-Ig display normal Ig production and develop 
normal germinal centers in response to a soluble TD-antigen, 
an observation the authors attribute to the poor binding of 
the  soluble monomeric CD40-Ig  construct  to  the CD40 
ligand, gp39. Consistent with the finding that CD40-Ig does 
not inhibit all gp39-dependent Ab responses, Gray et al. (46) 
demonstrate that in vivo administration of CD40-Ig does not 
block the formation of germinal centers. The fact that these 
authors do demonstrate inhibition of other gp39-dependent 
Ab responses  suggests that the gp39-CD40 interactions in- 
volved in germinal center formation may be more stringent 
and therefore more difficult to block in vivo. Thus, it is likely 
that the failure of CD40-Ig to inhibit germinal center for- 
mation is due to the inefficient blocking ability of this re- 
agent rather than the lack of a role for gp39 in germinal center 
formation. We believe that our data using a mAb previously 
shown to be efficient at blocking humoral responses in vivo 
(4, 5) provide strong evidence that gp39-CD40 interactions 
are essential  for the development of germinal centers. 
The histologic location at which gp39-expressing Th cells 
interact with resting B cells to initiate activation and differen- 
tiation to germinal center B cells is still unclear.  Expression 
of gp39 on Th cells in situ after antigen administration has 
been shown to be restricted to the outer PALS and around 
the terminal arterioles  (5). Although some gp39 § Th cells 
have been detected in the follicles of human tonsils,  lymph 
nodes, and spleen  (47),  gp39-expressing Th cells have not 
been detected in murine splenic germinal centers or marginal 
zones (5). These data indicate that the site of T-B interaction 
is likely to be in the PALS, suggesting that the initial site 
of B cell activation is outside the follicles. If this is the case, 
one could suggest that as a result of gp39-CD40  interac- 
tions, activated B cells migrate to the follicles, become com- 
petent to proliferate within the follicular microenvironment, 
and subsequently differentiate to form germinal centers. 
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